Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV
The purpose of this study is to determine whether the recombinant human EGF-rP64K/Montanide ISA 51 vaccine is safe, immunogenic and effective in the treatment of stage IIIb/IV non-small-cell lung cancer (NSCLC).
Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV
BIOLOGICAL: Recombinant Human rEGF-P64K/Montanide Vaccine
Survival, Two and a half years
Assessment of immunogenecity, safety as well as preliminary assessment of objective response, time of progression and quality of life, Two and a half years
The purpose of this study is to determine whether the recombinant human EGF-rP64K/Montanide ISA 51 vaccine is safe, immunogenic and effective in the treatment of stage IIIb/IV non-small-cell lung cancer (NSCLC).